Aprea Therapeutics, Inc.
APRE · NASDAQ
Market closed$0.709500$0.019500 (+2.83%)After hours $0.670400 · -5.51%
Key statistics
Previous close$0.690000
Open$0.686100
Day high$0.709600
Day low$0.650000
52-week high$2.22
52-week low$0.548000
Market cap4.61M
Volume74.52K
Average volume142.98K
P/E ratio-0.46
Forward P/E—
EPS-1.54
Dividend yield0.00%
Market context
Why it moved
APRE shares moved higher amid renewed buying interest supported by short-term technical momentum, as the stock rebounded from intraday lows with elevated volume signaling increased investor confidence in Aprea Therapeutics' near-term trajectory.
What is happening
Recent company-specific developments and publisher coverage.
Pluang · June 1, 2026Aprea Therapeutics shows early success with APR-1051 in advanced solid tumors at ASCO 2026.BioBuzz · April 21, 2026Greater Philadelphia-based Aprea Therapeutics Raises $30M to Extend Runway and Reposition Its Precision Oncology BetInvesting.com · March 30, 2026Aprea Therapeutics raises $30 million in private placementStocktwits · February 18, 2026Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In TrialTradingView · January 23, 2026Aprea Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or StandardMoomoo · August 14, 2025Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $10 Benzinga · June 1, 2026Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors Benzinga · May 14, 2026Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6 Mt Newswire · May 14, 2026Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating Benzinga · May 13, 2026Aprea Therapeutics Q1 EPS $(0.22) Beats $(0.23) Estimate Mt Newswire · May 7, 2026Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target Benzinga · May 7, 2026Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5 Benzinga · April 21, 2026Aprea Therapeutics To Present Abstract Titled 'Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)' At 2026 American Society Of Clinical Oncology Annual Meeting Benzinga · March 31, 2026Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target